Literature DB >> 32336813

Chapter 12. Antiviral Agents.

James L Kelley1.   

Abstract

This chapter discusses the agents with activity primarily against RNA viruses. The communicable diseases of the respiratory tract are probably the most common cause of symptomatic human infections. The viruses that are causative agents for human respiratory disease comprise the five taxonomically distinct families: orthomyxoviridae, paramyxoviridae, picornaviridae, coronaviridae, and adenoviridae. The influenza viruses, which consist of types A, B, and C, belong to the family orthomyxoviridae. Types A and B have been associated with significant increases in mortality during epidemics. The disease may be asymptomatic or cause symptoms ranging from the common cold to fatal pneumonia. Immunization against influenza has been recommended for high-risk groups and antiviral chemotherapy (amantadine) is available for the treatment and prophylaxis of all influenza A infections. There is both a great need for and interest in developing a chemotherapeutic agent for the treatment of these two viral, respiratory tract pathogens. The family picornaviridae contains the genus Rhinovirus that is composed of over a hundred distinct serotypes. Amantadine and rimantadine are specifically active against influenza A virus infections. The amantadine recipients reported a higher incidence of side effects largely attributed to the central nervous system (CNS) symptoms. This difference in side effects may be a pharmacokinetic phenomenon that results in higher plasma concentrations of amantadine. Significant progress continues to be made in the clinical use and development of agents active against DNA viruses. Acyclovir (9-(2-h droxyethoxymethyl)guanine) has been the subject of several reviews and of a syrnposium. Considerable progress has been made in evaluating the clinical promise of acyclovir; however, there remains much to be learned concerning the best use of this drug in clinical practice. Significant strides have been made in the development of clinically useful antiviral agents, especially against the DNA viruses of the herpes family. Most of these agents are directed against viral nucleic acid synthesis and require activation by a virus-induced thymidine kinase. Researchers have begun to focus on other strategies that may produce broader spectrum anti-viral agents with different mechanisms of action. © 1984 Academic Press Inc.

Entities:  

Year:  2008        PMID: 32336813      PMCID: PMC7172521          DOI: 10.1016/S0065-7743(08)60688-0

Source DB:  PubMed          Journal:  Annu Rep Med Chem        ISSN: 0065-7743            Impact factor:   1.059


  83 in total

1.  The activity of enviroxime against rhinovirus infection in man.

Authors:  R J Phillpotts; R W Jones; D C Delong; S E Reed; J Wallace; D A Tyrrell
Journal:  Lancet       Date:  1981-06-20       Impact factor: 79.321

Review 2.  The clinical pharmacology of acyclovir.

Authors:  H J Rogers; A S Fowle
Journal:  J Clin Hosp Pharm       Date:  1983-06

3.  An approach to inhibition of viral replication: inhibition of mRNA methylation.

Authors:  B B Goswami; O K Sharma; E Borek
Journal:  Recent Results Cancer Res       Date:  1983

4.  Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines.

Authors:  E J Dubovi; J D Geratz; S R Shaver; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

5.  Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro.

Authors:  R D Powers; J M Gwaltney; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

Review 6.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

7.  Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects.

Authors:  Y J Bryson; M Dillon; M Lovett; G Acuna; S Taylor; J D Cherry; B L Johnson; E Wiesmeier; W Growdon; T Creagh-Kirk; R Keeney
Journal:  N Engl J Med       Date:  1983-04-21       Impact factor: 91.245

8.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.

Authors:  E C Mar; Y C Cheng; E S Huang
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Antiviral effects if ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro.

Authors:  W C Koff; J L Elm; S B Halstead
Journal:  Antiviral Res       Date:  1982-05       Impact factor: 5.970

Review 10.  Viral respiratory illnesses.

Authors:  L J Anderson; P A Patriarca; J C Hierholzer; G R Noble
Journal:  Med Clin North Am       Date:  1983-09       Impact factor: 5.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.